They are top on my list of biotech picks at the moment. Great technology, which is much in demand by pharmas trying to extend patents on existing drugs.
As with many speculative small companies, they could burn the cash before hitting the big time, but the number of deals with big pharma companies would suggest a buyout might occur in that event.